文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

呋喹替尼对比安慰剂治疗经治转移性结直肠癌的FRESCO随机临床试验

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

FRESCO试验在中国28家医院纳入416例至少二线化疗后进展的转移性结直肠癌患者,2:1随机接受呋喹替尼或安慰剂。呋喹替尼组中位总生存期显著延长(9.3个月 vs 6.6个月,HR 0.65,P<.001),中位无进展生存期亦显著延长(3.7个月 vs 1.8个月,HR 0.26,P<.001)。

要点

  • 呋喹替尼三线及以上治疗转移性结直肠癌显著延长总生存期(HR 0.65)。
  • 中位无进展生存期呋喹替尼组3.7个月,安慰剂组1.8个月。
  • 3/4级治疗中出现不良事件发生率呋喹替尼组61.2%,安慰剂组19.7%。

核心结论

  • 在中国转移性结直肠癌患者中,至少二线化疗后进展者口服呋喹替尼较安慰剂显著延长总生存期。

研究设计与样本

  • FRESCO为随机、双盲、安慰剂对照、多中心(中国28家医院)3期临床试验。
  • 患者按2:1随机接受呋喹替尼5 mg(n=278)或安慰剂(n=138)口服,每日一次,服21天停7天,28天为一周期。
  • 主要终点为总生存期;关键次要终点包括无进展生存期、客观缓解率和疾病控制率。

主要发现

  • 呋喹替尼组中位总生存期9.3个月(95%CI 8.2-10.5),安慰剂组6.6个月(95%CI 5.9-8.1),死亡HR 0.65(95%CI 0.51-0.83,P<.001)。
  • 呋喹替尼组中位无进展生存期3.7个月(95%CI 3.7-4.6),安慰剂组1.8个月(95%CI 1.8-1.8),进展或死亡HR 0.26(95%CI 0.21-0.34,P<.001)。
  • 3级和4级治疗中出现不良事件发生率呋喹替尼组61.2%(170例),安慰剂组19.7%(27例)。
  • 严重不良事件发生率呋喹替尼组15.5%(43例),安慰剂组5.8%(8例);需住院者分别为14.4%(40例)和5.1%(7例)。

关键数值与推荐

  • 呋喹替尼用法为5 mg口服每日一次,服21天停7天,28天为一周期。
  • 入组条件为至少二线化疗后进展且未接受过VEGFR抑制剂治疗的转移性结直肠癌患者。

临床怎么用

  • 对于至少二线化疗后进展的中国转移性结直肠癌患者,可考虑口服呋喹替尼三线及以上治疗。
  • 用药期间需关注3/4级治疗中出现不良事件及严重不良事件。

局限性

  • 研究仅在中国患者中进行,结论外推至中国以外人群需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options. OBJECTIVE: To evaluate the efficacy and safety of oral fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, as third-line or later therapy in patients with metastatic CRC. DESIGN, SETTING, AND PARTICIPANTS: FRESCO (Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients) was a randomized, double-blind, placebo-controlled, multicenter (28 hospitals in China), phase 3 clinical trial. From December 2014 to May 2016, screening took place among 519 patients aged 18 to 75 years who had metastatic CRC that progressed after at least 2 lines of chemotherapy but had not received VEGFR inhibitor therapy; 416 met the eligibility criteria and were stratified by prior anti-VEGF therapy and K-ras status. The final date of follow-up was January 17, 2017. INTERVENTIONS: Patients were randomized in a 2:1 ratio to receive either fruquintinib, 5 mg (n = 278) or placebo (n = 138) orally, once daily for 21 days, followed by 7 days off in 28-day cycles, until disease progression, intolerable toxicity, or study withdrawal. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival. Key secondary efficacy endpoints were progression-free survival (time from randomization to disease progression or death), objective response rate (confirmed complete or partial response), and disease control rate (complete or partial response, or stable disease recorded ≥8 weeks postrandomization). Duration of response was also assessed. Safety outcomes included treatment-emergent adverse events. RESULTS: Of the 416 randomized patients (mean age, 54.6 years; 161 [38.7%] women), 404 (97.1%) completed the trial. Median overall survival was significantly prolonged with fruquintinib compared with placebo (9.3 months [95% CI, 8.2-10.5] vs 6.6 months [95% CI, 5.9-8.1]); hazard ratio (HR) for death, 0.65 (95% CI, 0.51-0.83; P < .001). Median progression-free survival was also significantly increased with fruquintinib (3.7 months [95% CI, 3.7-4.6] vs 1.8 months [95% CI, 1.8-1.8] months); HR for progression or death, 0.26 (95% CI, 0.21 to 0.34; P < .001). Grades 3 and 4 treatment-emergent adverse events occurred in 61.2% (170) of patients who received fruquintinib and 19.7% (27) who received placebo. Serious adverse events were reported by 15.5% (43) of patients in the fruquintinib group and 5.8% (8) in the placebo group, with 14.4% (40) of fruquintinib-treated and 5.1% (7) of placebo-treated patients requiring hospitalization. CONCLUSIONS AND RELEVANCE: Among Chinese patients with metastatic CRC who had tumor progression following at least 2 prior chemotherapy regimens, oral fruquintinib compared with placebo resulted in a statistically significant increase in overall survival. Further research is needed to assess efficacy outside of China. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02314819.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Li J, Qin S, Xu RH, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018. PMID: 29946728. doi:10.1001/jama.2018.7855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。